Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Thyritope Biosciences
c/o COI Pharmaceuticals
11099 North Torrey Pines Road, Suite 290
La Jolla, CA 92037
http://www.coipharma.com/portfolio/thyritope-biosciences/

Thyritope Biosciences is developing therapeutics that target thyroid stimulating auto-antibodies, which are the causative drivers of Graves' hyperthyroidism and Graves' orbitopathy. Graves' disease is an autoimmune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. The same antibodies stimulate the tissue around the eyes, resulting in an increase of orbital fat and extra-ocular muscle volume which causes the bulging of the eyes characteristic of Graves' orbitopathy. While there are existing treatments to manage Graves' hyperthyroidism, these treatments do not address the underlying cause of the disease. There is currently no approved treatment for Graves' orbitopathy. Thyritope was founded based on molecular evolution technology developed by Patrick Daugherty, Ph.D., Professor of Chemical Engineering, and Biomolecular Science and Engineering at the University of California, Santa Barbara and commercialized by Serimmune, Inc.

Key Contact
Name
Jay Lichter
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
09/22/14 $10,000,000 Series A Avalon Ventures
GlaxoSmithKline
undisclosed